

*A2* the specific compounds disclosed in the Examples and, where the document is a patent, the claims of those documents.

**In the Claims:**

Please cancel claims 1-20 and replace them with new claims 21-29 as follows:

*Sub B1*  
21. (new) A method of treatment of sexual dysfunction which comprises administering by inhalation an effective amount of an inhibitor of cGMP PDE 5 in an atomisable composition or a finely divided particulate form to a subject in need of such treatment.

22. (new) A method according to claim 21, in which said inhibitor is a pyrazolopyrimidinone or an aminoquinazoline derivative.

23. (new) A method according to claim 22, in which said inhibitor is a 4-aminoquinazoline derivative, an arylpyrazolopyrimidinone or a 6-heterocycl-yl-pyrazolo[3,4-d]pyrimidin-4-one.

*B3*  
*A3*  
24. (new) A method according to claim 23, in which said inhibitor is 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]-pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenyl-methylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methane-sulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

25. (new) A method according to claim 21, in which said atomisable composition is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

26. (new) A method according to claim 21, in which said inhibitor in finely divided particulate form is inhaled together with a particulate carrier.

27. (new) A medicament comprising 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)-quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, or 1,3-dimethyl-6-